Did you know?

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...Corcept prides itself on a dynamic culture which remains true to its values while embracing continued growth and change. Our work is marked by innovation, integrity, rigor, transparent communication, and collaboration. We all have unique contributions to make, and our success is the sum of those contributions. Join us! Research Corcept Therapeutics' (Nasdaq:CORT) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance ...Corcept Therapeutics, a Silicon Valley-based drug company, began marketing Korlym six years ago as a specialty drug for about 10,000 rare-disease patients such as Edwin. The difference in price between Korlym and Mifeprex is striking, even though the ingredients are the same: One 200-milligram pill to prompt an abortion costs about …WebNov 1, 2023 · Corcept’s third quarter 2023 revenue was $123.6 million, compared to $101.7 million in the third quarter of 2022. Third quarter operating expenses were $92.4 million, compared to $69.8 million in the third quarter of 2022, due to increased clinical trial activity and expenses to support the expansion of our clinical development and commercial ... Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Additional Information Regarding the ...If you are in the USA, by sending an email with your request to [email protected] or by calling us and leaving a voice message at 1-855-212-CORT (1-855-212-2678) If you are in the EEA/UK area, by sending an email to [email protected]; Please note that we will endeavour to process your request as soon as possible.Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological ...WebJul 17, 2023 · Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Alternative Names: ADS-108297; CORT-108297. Latest Information Update: 29 Nov 2022. Price : $50 *. Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may vary according to local VAT and billing address. Your purchase entitles you to full access to the information contained in ...WebA class action complaint has been filed against Corcept, which alleges that defendants made materially false and/or misleading statements, and failed to ...Corcept’s fourth quarter 2022 revenue was $103.1 million, compared to $98.8 million in the fourth quarter of 2021. Revenue for the full year was $401.9 million, compared to $366.0 million in 2021. The company expects 2023 revenue of $430 – $450 …In accordance with the terms and conditions of the Tender Offer, based on these preliminary results, Corcept expects to purchase 6,630,151 shares of common stock at a purchase price of $22.00 per ...Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol.MENLO PARK, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update ...Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological ...Web

Sep 30, 2023 · Corcept’s third quarter 2023 revenue was $123.6 million, compared to $101.7 million in the third quarter of 2022. Third quarter operating expenses were $92.4 million , compared to $69.8 million in the third quarter of 2022, due to increased clinical trial activity and expenses to support the expansion of our clinical development and ... Corcept’s drug Korlym ® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking StatementsWebMar 28, 2023 · Corcept’s drug Korlym ® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking Statements Dec 8, 2022 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...

Corcept is a biopharmaceutical company that develops cortisol modulators, drugs that block the glucocorticoid receptor (GR) and reduce cortisol levels. Corcept's products are designed to treat endocrine, metabolic, oncologic, and psychiatric disorders, such as …Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Jun 6, 2022 · Corcept has discovered a large por. Possible cause: Oval shaped, light yellow to yellow tablets debossed with “Corcept” on one si.